

Press Release

29th of Sep 2021

ISR has signed agreement with principal investigators to initiate vaccine study

ISR has signed an agreement with the principal investigators Prof. Dr. ABM Abdullah and Prof. Dr. Ahmedul Kabir from Mugda Medical College hospital in Dhaka, Bangladesh in order to conduct the company's vaccination study for SARS-CoV-2.

" The team in Bangladesh, with experienced clinical investigators, have worked intensively together with ISR to put the clinical trial protocol together for the vaccination study. With the contract in place with the principal investigators we are now looking forward to submit the application to Bangladesh Medical Research Council, BMRC in Bangladesh, in order to receive approval to initiate the clinical study", comments Ola Winqvist, CEO ISR.

ISR's spike based candidate vaccine will be evaluated in a phase I double blind placebo controlled clinical trial with regards to safety, dose, route of administration, immunogenicity and effect of inhalation/nasal formulations. The study will include 180 healthy volunteers, half who will receive inhalation and half intranasal application of the vaccine. With CRO and principal investigators in place the clinical protocol and documentation necessary for the application to ethics committee and BMRC can be finalized.

For further information, please contact:

Ola Winqvist

CEO, ISR Immune System Regulation Holding AB (publ)

E-post: ola.winqvist@israb.se

Phone: +46 (0)70 5427939

About ISR Immune System Regulation Holding AB (publ)

ISR is an innovation driven pharmaceutical development company within immunotherapy. The company focuses on clinical and preclinical research, with the goal to develop a broad-spectrum antiviral platform of immune regulating pharmaceuticals. Mangold is the company's Certified Adviser, and can be reached on phone +46 (0)8-463 80 00.

www.israb.se

This information is subject to compulsory publication by Immune System Regulation Holding AB (publ) complying with EU's Market Abuse Regulation (MAR), and the Market Abuse Act